Tandem Diabetes Care
TNDM
303 hedge funds and large institutions have $5.75B invested in Tandem Diabetes Care in 2021 Q2 according to their latest regulatory filings, with 56 funds opening new positions, 109 increasing their positions, 94 reducing their positions, and 41 closing their positions.
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
150% more call options, than puts
Call options by funds: $86.1M | Put options by funds: $34.4M
37% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 41
16% more repeat investments, than reductions
Existing positions increased: 109 | Existing positions reduced: 94
13% more capital invested
Capital invested by funds: $5.08B → $5.75B (+$669M)
4% more funds holding
Funds holding: 290 → 303 (+13)
2.17% more ownership
Funds ownership: 92.07% → 94.25% (+2.2%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$87.3M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$79.2M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$74.1M |
| 4 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$44M |
| 5 |
State Street
Boston,
Massachusetts
|
+$30.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VOYA Investment Management
Atlanta,
Georgia
|
-$64.7M |
| 2 |
AAM
Ardevora Asset Management
London,
United Kingdom
|
-$54.3M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$30.8M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$27.9M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$22.6M |
TNDM Hedge Fund Activity: Q2 2021 in Review
303 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Tandem Diabetes Care (TNDM) for Q2 2021, worth a combined $5.75B — up 13% from $5.08B a quarter earlier.
Buyers outnumbered sellers: 56 funds opened new TNDM positions and 41 closed out — a net gain of 15 holders — while 109 added to existing stakes and 94 trimmed.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $87.3M. The largest seller was VOYA Investment Management, cutting an estimated $64.7M.
- 303 institutional investors held Tandem Diabetes Care (TNDM) as of Q2 2021, up from 290 in Q1 2021.
- Funds reported $5.75B of Tandem Diabetes Care stock for Q2 2021, up 13% quarter-over-quarter.
- 56 funds opened new Tandem Diabetes Care positions in Q2 2021 and 41 closed out, a net change of +15 holders.
- The largest Tandem Diabetes Care buyer in Q2 2021 was Consonance Capital Management, an estimated $87.3M added.
- The largest Tandem Diabetes Care seller in Q2 2021 was VOYA Investment Management, an estimated $64.7M sold.
Based on aggregated 13F filings for Q2 2021.